Precision BioSciences financials
$6.18−0.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jun 30 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 | Q2 '23 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $34.2M | $13.0K | $18.0K | $29.0K | $638.0K | $576.0K | $49.9M | $17.6M | $7.0M | $13.1M | $19.8M |
| Gross profit | $0.00 | $34.2M | $13.0K | $18.0K | $29.0K | $638.0K | $576.0K | $49.9M | $17.6M | $7.0M | $13.1M | $19.8M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$19.2M | $12.5M | -$20.7M | -$21.9M | -$22.1M | -$24.8M | -$21.3M | $24.1M | -$4.2M | -$14.9M | -$12.4M | -$3.1M |
| Net income | -$32.7M | $20.1M | -$21.8M | -$23.5M | -$20.6M | -$17.7M | -$16.4M | $32.7M | $8.6M | -$16.3M | -$8.1M | -$11.9M |
| Net margin | — | 58.9% | −167476.9% | −130666.7% | −70913.8% | −2781.3% | −2851.6% | 65.6% | 48.8% | −231.4% | −61.6% | −60.1% |
| Diluted EPS | $-1.26 | $1.05 | $-1.84 | $-2.13 | $-2.21 | $-2.17 | $-2.25 | $4.67 | $1.70 | $-4.06 | $-2.10 | $-3.13 |
| EBITDA | -$19.2M | $12.9M | -$20.3M | -$21.5M | -$21.7M | -$24.4M | -$20.6M | $25.2M | -$3.0M | -$13.6M | -$10.7M | -$1.2M |
| Operating cash flow | — | -$11.3M | -$15.3M | -$20.3M | -$19.1M | -$18.7M | -$5.9M | -$14.9M | -$19.0M | -$8.4M | -$23.1M | -$21.1M |
| Free cash flow | — | -$11.3M | -$15.3M | -$20.3M | -$19.1M | -$18.8M | -$6.0M | -$14.9M | -$19.1M | -$8.4M | -$23.5M | -$22.2M |
| Diluted shares | 25.9M | 19.1M | 11.8M | 11.0M | 9.3M | 8.2M | 7.3M | 7.0M | 5.1M | 4.0M | 3.8M | 3.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $86.1M | $99.4M | $110.8M | $44.9M | $62.2M | $77.2M |
| Short-term investments | $1.5M | $1.8M | $4.8M | $0.00 | $0.00 | $0.00 |
| Total debt | $22.4M | $22.4M | $22.4M | $22.4M | $22.4M | $22.3M |
| Total assets | $125.9M | $143.9M | $154.4M | $93.5M | $108.9M | $124.4M |
| Total liabilities | $80.6M | $67.8M | $62.2M | $76.9M | $74.9M | $75.1M |
| Shareholders' equity | $45.3M | $76.1M | $92.2M | $16.6M | $34.1M | $49.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology